LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS FROM THE BALANCE-EXTEND OPEN-LABEL EXTENSION STUDY

被引：0
|
作者：
Kivitz, A. [1 ]
Wells, A. F. [2 ]
Vargas, J. Ignacio [3 ]
Baraf, H. S. B. [4 ,5 ]
Rischmueller, M. [6 ,7 ,8 ]
Klaff, J. [9 ]
Khan, N. [9 ]
Li, Y. [9 ]
Carter, K. [9 ]
Friedman, A. [9 ]
Durez, P. [10 ]
机构：
[1] Altoona Ctr Clin Res, Altoona Arthrit Osteoporosis Ctr, Duncansville, PA USA
[2] Aurora Rheumatol & Immunotherapy Ctr, Dept Rheumatol, Franklin, WI USA
[3] Quantum Res, Med, Las Lagos, Chile
[4] Ctr Rheumatol & Bone Res, Rheumatol, Wheaton, MD USA
[5] George Washington Univ, Rheumatol, Washington, DC USA
[6] Queen Elizabeth Hosp, Dept Rheumatol, Woodville, SA, Australia
[7] Basil Hetzel Inst, Rheumatol Res Grp, Woodville, SA, Australia
[8] Univ Adelaide, Adelaide Med Sch, Rheumatol, Adelaide, SA, Australia
[9] AbbVie Inc, Immunol, N Chicago, IL USA
[10] UCLouvain St Luc, Inst Rech Experimentale & Clin Univ St Luc, Brussels, Belgium
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1819
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0685
引用
收藏
页码：620 / 621
页数：2
相关论文
共 50 条
  • [1] Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
    Alan Kivitz
    Alvin F. Wells
    Juan I. Vargas
    Herbert S. B. Baraf
    Maureen Rischmueller
    Justin Klaff
    Nasser Khan
    Yihan Li
    Kyle Carter
    Alan Friedman
    Patrick Durez
    Rheumatology and Therapy, 2023, 10 : 901 - 915
  • [2] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS FROM THE BALANCE-EXTEND OPEN-LABEL EXTENSION STUDY
    Kivitz, Alan
    Wells, Alvin F.
    Vargas, Juan I.
    Baraf, Herbert S. B.
    Rischmueller, Maureen
    Klaff, Justin
    Khan, Nasser
    Li, Yihan
    Carter, Kyle
    Friedman, Alan
    Durez, Patrick
    RHEUMATOLOGY, 2023, 62
  • [3] Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
    Kivitz, Alan
    Wells, Alvin F. F.
    Vargas, Juan I. I.
    Baraf, Herbert S. B.
    Rischmueller, Maureen
    Klaff, Justin
    Khan, Nasser
    Li, Yihan
    Carter, Kyle
    Friedman, Alan
    Durez, Patrick
    RHEUMATOLOGY AND THERAPY, 2023, 10 (04) : 901 - 915
  • [4] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
    Feist, Eugen
    Nasonov, Evgeny
    Luggen, Michael
    Fatenejad, Saeed
    Grishin, Sergey
    Samsonov, Mikhail
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
  • [5] LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Banerji, A.
    Hao, J.
    Yu, M.
    Bernstein, J.
    Johnston, D.
    Riedl, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S21 - S21
  • [6] An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
    Cohen, Stanley
    Pablos, Jose L.
    Pavelka, Karel
    Mueller, Gerard Anton
    Matsumoto, Alan
    Kivitz, Alan
    Wang, Hui
    Krishnan, Eswar
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [7] An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
    Stanley Cohen
    Jose L. Pablos
    Karel Pavelka
    Gerard Anton Müller
    Alan Matsumoto
    Alan Kivitz
    Hui Wang
    Eswar Krishnan
    Arthritis Research & Therapy, 21
  • [8] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Jürgen Wollenhaupt
    Eun-Bong Lee
    Jeffrey R. Curtis
    Joel Silverfield
    Ketti Terry
    Koshika Soma
    Chris Mojcik
    Ryan DeMasi
    Sander Strengholt
    Kenneth Kwok
    Irina Lazariciu
    Lisy Wang
    Stanley Cohen
    Arthritis Research & Therapy, 21
  • [9] Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis
    Keystone, Ed
    Taylor, Peter
    Genovese, Mark
    Schlichting, Douglas
    de la Torre, Inmaculada
    Beattie, Scott
    Rooney, Terence
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1292 - 1292
  • [10] SAFETY AND EFFICACY OF BARICITINIB THROUGH 128 WEEKS IN AN OPEN-LABEL, LONG-TERM EXTENSION STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Keystone, E.
    Taylor, P.
    Genovese, M.
    Schlichting, D.
    De La Torre, I
    Beattie, S.
    Rooney, T.
    Suters, A.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 26 - 26
12345